| EGFR-TKIs治疗非小细胞肺癌进展 |
| |
| 引用本文： | 谭芬来,王印祥,袁晓玢,丁列明,胡蓓,张力,周建英,申屠建中,孙燕.EGFR-TKIs治疗非小细胞肺癌进展[J].中国新药杂志,2011(17). |
| |
| 作者姓名： | 谭芬来 王印祥 袁晓玢 丁列明 胡蓓 张力 周建英 申屠建中 孙燕 |
| |
| 作者单位： | 浙江贝达药业有限公司;中国医学科学院北京协和医院;浙江大学医学院附属第一医院;中国医学科学院肿瘤医院; |
| |
| 摘 要： | 目前,肺癌依然是导致人类恶性肿瘤死亡的首位疾病。在过去10年中,EGFR-TKI药物的出现,显著改善了患者的生存,从而改变了肺癌的标准治疗模式。作为一线、二线或其他治疗,EGFR-TKI药物,包括吉非替尼和厄洛替尼,在特定人群中(腺癌、女性、非吸烟、亚裔患者)疗效显著。除上述两种药物,由浙江贝达药业有限公司研发的EGFR-TKIs埃克替尼也已经完成了其III期临床试验(ICOGEN),并取得可喜的结果。本文将对以上3种EGFR-TKI药物治疗非小细胞肺癌进展进行综述。
|
| 关 键 词： | EGFR-TKIs 非小细胞肺癌 埃克替尼 吉非替尼 厄洛替尼 |
Targeted therapy for non-small-cell lung cancer using EGFR-TKIs |
| |
| TAN Fen-lai,WANG Yin-xiang,YUAN Xiao-fen,DING Lie-ming,HU Bei,ZHANG Li,ZHOU Jian-ying,SHENG-TU Jian-zhong,SUN Yan.Targeted therapy for non-small-cell lung cancer using EGFR-TKIs[J].Chinese Journal of New Drugs,2011(17). |
| |
| Authors: | TAN Fen-lai WANG Yin-xiang YUAN Xiao-fen DING Lie-ming HU Bei ZHANG Li ZHOU Jian-ying SHENG-TU Jian-zhong SUN Yan |
| |
| Institution: | TAN Fen-lai1,WANG Yin-xiang1,YUAN Xiao-fen1,DING Lie-ming1,HU Bei2,ZHANG Li2,ZHOU Jian-ying3,SHENG-TU Jian-zhong3,SUN Yan4(1 Zhejiang BetaPharma.Inc.,Hangzhou 311100,China,2 Perking Union Medical Hospital,Beijing 100730,3 The First Affiliated Hospital of Medical School of Zhejiang University,Hangzhou 310003,4 Cancer Hospital,Chinese Academy of Medical Science,Beijing 100021,China) |
| |
| Abstract: | Non-small cell lung cancer(NSCLC) is the leading cause of cancer mortality worldwide.The management of NSCLC has changed dramatically in the last decade.A number of well documented clinical studies demonstrated that the epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) showed a better survival benefit comparing to the standard treatments in patients with advanced/metastatic NSCLC.EGFR-TKIs,including gefitinib and erlotinib,have been used in first-line,second-line and more other settings... |
| |
| Keywords: | EGFR-TKIs NSCLC icotinib gefitinib erlotinib |
| 本文献已被 CNKI 等数据库收录！ |
|
